دورية أكاديمية
Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows
| العنوان: | Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows |
|---|---|
| المؤلفون: | Guarino, Maria, Sessa, Anna, Cossiga, Valentina, Morando, Federica, Caporaso, Nicola, Morisco, Filomena, Luca, Viganó, Romana, Ponziani Francesca, Maurizio, Pompili, Cillo, Umberto, Burra, Patrizia, Mescoli, Claudia, Gambato, Martina, Paolo, Russo Francesco, Alessandro, Vitale, Giuseppe, Cabibbo, Mauro, Vigano', Giovanni, Galati, Erica, Villa, Lupo, Luigi G., Maria, Rendina, Losito, Francesco, Fucilli, Fabio, Persico, Marcello, D'Ambrosio, Roberta, Sangiovanni, Angelo, Massimo, Iavarone, Giuseppina, Brancaccio, Cucchetti, Alessandro, Renzulli, Matteo, Franco, Trevisani, Miele, Luca, Grieco, Antonio, Rapaccini, Gianlodovico, Gasbarrini, Antonio, Sandri, Giovanni Battisa Levi, Melandro, Fabio, Rossi, Massimo, Quirino, Lai, Lenci, Ilaria, Manzia, Tommaso Maria, Tortora, Raffaella, Di Costanzo, Giovan Giuseppe, Ghinolfi, Davide, Rreka, Erion, Carrai, Paola, Simonetti, Natalia, Rodolfo, Sacco, Sposito, Carlo, Bhoori, Sherrie, Di Sandro, Stefano, Foschi, Francesco Giuseppe, Gardini, Andrea Casadei, Nicolini, Daniele, Mazzocato, Susanna, Alba, Kostandini, Violi, Paola, Baccarani, Umberto, Pravisani, Riccardo, Vincenzi, Valter |
| المساهمون: | Guarino, Maria, Sessa, Anna, Cossiga, Valentina, Morando, Federica, Caporaso, Nicola, Morisco, Filomena, Luca, Viganó, Romana, Ponziani Francesca, Maurizio, Pompili, Cillo, Umberto, Burra, Patrizia, Mescoli, Claudia, Gambato, Martina, Russo, FRANCESCO PAOLO, Vitale, Alessandro, Giuseppe, Cabibbo, Mauro, Vigano', Giovanni, Galati, Erica, Villa, Lupo, Luigi G., Maria, Rendina, Losito, Francesco, Fucilli, Fabio, Persico, Marcello, D'Ambrosio, Roberta, Sangiovanni, Angelo, Massimo, Iavarone, Brancaccio, Giuseppina, Cucchetti, Alessandro, Renzulli, Matteo, Franco, Trevisani, Miele, Luca, Grieco, Antonio, Rapaccini, Gianlodovico, Gasbarrini, Antonio, Sandri, Giovanni Battisa Levi, Melandro, Fabio, Rossi, Massimo, Quirino, Lai, Lenci, Ilaria, Manzia, Tommaso Maria, Tortora, Raffaella, Di Costanzo, Giovan Giuseppe, Ghinolfi, Davide, Rreka, Erion, Carrai, Paola, Simonetti, Natalia, Rodolfo, Sacco, Sposito, Carlo, Bhoori, Sherrie, Di Sandro, Stefano, Foschi, Francesco Giuseppe, Gardini, Andrea Casadei, Nicolini, Daniele, Mazzocato, Susanna, Alba, Kostandini, Violi, Paola, Baccarani, Umberto, Pravisani, Riccardo, Vincenzi, Valter |
| بيانات النشر: | Baishideng Publishing Group Co., Limited |
| سنة النشر: | 2018 |
| المجموعة: | Padua Research Archive (IRIS - Università degli Studi di Padova) |
| مصطلحات موضوعية: | Direct-acting antiviral agent, Hepatitis C viru, Hepatocellular carcinoma, Occurrence, Recurrence, Antiviral Agent, Carcinoma, Hepatocellular, Disease Progression, Hepaciviru, Hepatitis C, Chronic, Human, Incidence, Liver, Liver Neoplasm, Neoplasm Recurrence, Local, Risk Factor, Sustained Virologic Response, Treatment Outcome, Gastroenterology |
| الوصف: | With the introduction of direct-acting antiviral agents (DAA), the rate of sustained virological response (SVR) in the treatment of hepatitis C virus (HCV) has radically improved to over 95%. Robust scientific evidence supports a beneficial role of SVR after interferon therapy in the progression of cirrhosis, resulting in a decreased incidence of hepatocellular carcinoma (HCC). However, a debate on the impact of DAAs on the development of HCC is ongoing. This review aimed to analyse the scientific literature regarding the risk of HCC in terms of its recurrence and occurrence after the use of DAAs to eradicate HCV infection. Among 11 studies examining HCC occurrence, the de novo incidence rate ranged from 0 to 7.4% (maximum follow-up: 18 mo). Among 18 studies regarding HCC recurrence, the rate ranged from 0 to 54.4% (maximum "not well-defined" followup: 32 mo). This review highlights the major difficulties in interpreting data and reconciling the results of the included studies. These difficulties include heterogeneous cohorts, potential misclassifications of HCC prior to DAA therapy, the absence of an adequate control group, short follow-up times and different kinds of follow-up. Moreover, no clinical feature-based scoring system accounts for the molecular characteristics and pathobiology of the tumours. Nonetheless, this review does not suggest that there is a higher rate of de novo HCC occurrence or recurrence after DAA therapy in patients with previous HCV infection. © 2018 The Author(s). Published by Baishideng Publishing Group Inc. All rights reserved. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | STAMPA |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/29962815; info:eu-repo/semantics/altIdentifier/wos/WOS:000437746200004; volume:24; issue:24; firstpage:2582; lastpage:2595; numberofpages:14; journal:WORLD JOURNAL OF GASTROENTEROLOGY; http://hdl.handle.net/11577/3287793Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85049299671; https://www.f6publishing.com/forms/main/DownLoadFile.aspx?Type=Digital&TypeId=1&id=10.3748%2fwjg.v24.i24.2582&FilePath=77AD0785A3FF5EE9CBE56CB8F1ADAFAD26BFCDBAC66F5FFAB3BA24E1964ADA6F0BDDD174FCD54C870D01B4F0603BDD84AFAC59DAF125038CTest |
| DOI: | 10.3748/wjg.v24.i24.2582 |
| الإتاحة: | https://doi.org/10.3748/wjg.v24.i24.2582Test http://hdl.handle.net/11577/3287793Test https://www.f6publishing.com/forms/main/DownLoadFile.aspx?Type=Digital&TypeId=1&id=10.3748%2fwjg.v24.i24.2582&FilePath=77AD0785A3FF5EE9CBE56CB8F1ADAFAD26BFCDBAC66F5FFAB3BA24E1964ADA6F0BDDD174FCD54C870D01B4F0603BDD84AFAC59DAF125038CTest |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.AEF897BA |
| قاعدة البيانات: | BASE |
| DOI: | 10.3748/wjg.v24.i24.2582 |
|---|